Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...
Product Name : Totect
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2023
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.
Product Name : Totect
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
